A phase 1/2a clinical trial to assess safety and immunogenicity of an adenoviral-vectored capsular group B meningococcal vaccine

Overview of attention for article published in Science Translational Medicine, May 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

news: 3 news outlets
blogs: 1 blog
policy: 1 policy source

twitter: 9 X users
bluesky: 3 Bluesky users

Readers on

mendeley: 9 Mendeley

So far, Altmetric has seen 3 Bluesky posts from 3 Bluesky users, with an upper bound of 4,545 followers.

A new gene-based vaccine targeting group B meningococcus has demonstrated safety and strong immune responses in healthy adults, supporting further development for broader protection. doi.org/g9kcr3

The group B meningococcus adenovirus-based vaccine ChAdOx1 MenB.1 is safe and immunogenic in healthy volunteers www.science.org/doi/10.1126/...

www.science.org/doi/10.1126/... 🧪

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity.